<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033384</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069279</org_study_id>
    <secondary_id>UAB-0152</secondary_id>
    <secondary_id>PFIZER-1040-002-004</secondary_id>
    <secondary_id>UAB-F011203011</secondary_id>
    <secondary_id>NCI-G02-2052</secondary_id>
    <nct_id>NCT00033384</nct_id>
  </id_info>
  <brief_title>CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Multicenter Phase 2 Study of CI-1040 In Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer Or Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer&#xD;
      cell growth and by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have&#xD;
      metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of CI-1040 in patients with non-small cell lung,&#xD;
           breast, colon, or pancreatic cancer.&#xD;
&#xD;
        -  Determine the safety profile of this drug in these patients.&#xD;
&#xD;
        -  Assess quality of life (overall and for each tumor type) of patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the relationship between study drug concentration and antitumor response in&#xD;
           these patients and target suppression and safety of this drug.&#xD;
&#xD;
        -  Correlate target suppression (pERK) with antitumor effects of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate the mRNA expression profile of the tumors with antitumor effects of this drug&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to tumor type&#xD;
      (non-small cell lung vs breast vs colon vs pancreas).&#xD;
&#xD;
      Patients receive oral CI-1040 twice daily on days 1-21. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 28 days during the first 6 months of&#xD;
      study therapy.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 52-172 patients (13-43 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-1040</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or inoperable non-small cell&#xD;
             lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas&#xD;
&#xD;
          -  Bidimensionally measurable lesions that are not previously irradiated&#xD;
&#xD;
               -  New lesions that have developed in a previously irradiated field may be used as&#xD;
                  measurable disease&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
               -  Patients with prior brain metastases are allowed provided they have undergone&#xD;
                  prior resection of metastases and/or 1 prior course of cranial irradiation, have&#xD;
                  no new sites of brain metastases since then, have no worsening CNS symptoms, and&#xD;
                  have discontinued prior corticosteroids for at least 30 days&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT no greater than 2 times ULN (5 times ULN if due to liver involvement)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after study&#xD;
             participation&#xD;
&#xD;
          -  Capable of swallowing intact study medication capsules&#xD;
&#xD;
          -  Capable of following instructions regarding study medication or has daily caregiver to&#xD;
             administer study medication&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No life-threatening illness unrelated to tumor&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 3 years except nonmelanoma&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior immunotherapy or biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No more than 1 prior cytotoxic chemotherapy regimen for metastatic non-small cell lung&#xD;
             or colon cancer&#xD;
&#xD;
          -  No more than 2 prior cytotoxic chemotherapy regimens for breast cancer&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy for pancreatic cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since other prior hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J. Rinehart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>July 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2003</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>duct cell adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

